VBI Vaccines Inc. (VBV) Analysts See $-0.31 EPS

February 24, 2018 - By Marry Poplack

 VBI Vaccines Inc. (VBV) Analysts See $ 0.31 EPS

Analysts expect VBI Vaccines Inc. (TSE:VBV) to report $-0.31 EPS on March, 23.They anticipate $0.07 EPS change or 29.17 % from last quarter’s $-0.24 EPS. After having $-0.30 EPS previously, VBI Vaccines Inc.’s analysts see 3.33 % EPS growth. The stock increased 3.81% or $0.18 during the last trading session, reaching $4.9. About 2,702 shares traded. VBI Vaccines Inc. (TSE:VBV) has 0.00% since February 24, 2017 and is . It has underperformed by 16.70% the S&P500.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $317.21 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

More recent VBI Vaccines Inc. (TSE:VBV) news were published by: Seekingalpha.com which released: “VBI Vaccines Might Be A Recovery Play After A Dip” on August 18, 2017. Also Globenewswire.com published the news titled: “VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical …” on January 17, 2018. Streetinsider.com‘s news article titled: “Form 8-K VBI Vaccines Inc/BC For: Feb 19” with publication date: February 23, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: